蘇大維格(300331.SZ):“面向柔性光電子的微納製造關鍵技術與應用”項目獲國家科學技術進步獎二等獎
格隆匯1月10日丨蘇大維格(300331.SZ)公佈,2020年1月10日,2019年度國家科學技術獎勵大會在北京召開,公司與蘇州大學合作承擔的“面向柔性光電子的微納製造關鍵技術與應用”項目獲得2019年度國家科學技術進步獎二等獎。
此次獲獎是對公司微納光學制造領域研發能力的充分肯定,對於推動公司先進技術的進一步研發與產業化佈局具有重要意義。未來,公司將繼續加大科研創新力度,持續推進新技術、新產品的研發,為公司業績的持續增長提供可靠保障,為股東創造更多的利益價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.